NCT06293950

Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: University of Jordan · Academic / Other
• Sex: All
• Age: 4 Years – 14 Years
• Healthy volunteers: Not accepted

Summary

Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities.

Detailed description

Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities. ASDs comprise heterogeneous and complex neuro-developmental pathologies with well-defined inflammatory conditions and immune system dysfunction. Due to neurobiological changes underlying ASD development, cell-based therapies have been proposed and applied to ASDs. Indeed, stem cells show specific immunologic properties, which make them promising candidates for ASD treatment.

Conditions

• Autism

Interventions

Type	Name	Description
BIOLOGICAL	WJMSC	\- Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.

Timeline

• Start date: 2022-03-09
• Primary completion: 2026-06-01
• Completion: 2027-12-01
• First posted: 2024-03-05
• Last updated: 2025-01-24

Locations

1 site across 1 country: Jordan